유방암 치료제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of breast cancer therapeutics Market

The global breast cancer therapeutics market size was valued at USD 34.59 billion in 2025 and is projected to grow from USD 37.98 billion in 2026 to USD 80.23 billion by 2034, registering a CAGR of 9.80% during 2026-2034. North America dominated the market with a 47.91% share in 2025. The market includes pharmaceutical therapies used to treat different forms and stages of breast cancer, including targeted therapy, hormonal therapy, chemotherapy, and immunotherapy.

The increasing global prevalence of breast cancer, growing awareness regarding early diagnosis, improving access to cancer treatment, and continuous pharmaceutical research are supporting market expansion. The development of targeted therapies and immunotherapies is particularly important as healthcare providers increasingly seek more specialized treatment options. Continuous product development, clinical trials, regulatory approvals, and launches of advanced therapeutics are expected to create further opportunities across developed and emerging healthcare markets.

Market Definition and Scope

The breast cancer therapeutics market covers pharmaceutical products and treatment approaches used for the management of breast cancer. The market is segmented according to therapy, cancer type, and distribution channel. Major therapies include targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. Cancer types include hormone receptor breast cancer and HER2-positive breast cancer, while distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

Market Dynamics

Drivers

Increasing breast cancer prevalence is a major factor supporting market growth. A large and expanding patient population creates sustained demand for effective therapeutic solutions. Greater awareness of breast cancer screening and improvements in diagnostic technologies are also contributing to earlier detection and treatment.

The launch of technologically advanced therapeutics is another important growth factor. Pharmaceutical companies are developing medicines designed to address specific biological characteristics of tumors and treatment-resistant disease. The availability of innovative therapies for previously difficult-to-treat breast cancers is expanding treatment possibilities.

Trends

Continuous research and development is a major trend in the industry. Leading pharmaceutical companies are investing in clinical research focused on targeted therapies, hormone receptor-positive breast cancer, HER2-positive disease, and metastatic breast cancer. Immunotherapy and other precision-based approaches are also gaining attention as treatment strategies become increasingly specialized.

The growing adoption of personalized treatment approaches is further influencing the market. Companion diagnostics and biomarker-based treatment selection are helping healthcare professionals identify therapies appropriate for specific patient groups.

Restraints

Adverse effects associated with breast cancer therapeutics may restrict market growth. Targeted therapies can cause skin problems, gastrointestinal complications, diarrhea, hypertension, and other reactions. Immunotherapies may also be associated with fatigue, nausea, and other adverse effects. Severe reactions can require treatment modification or discontinuation.

Impact of COVID-19

The COVID-19 pandemic affected cancer diagnosis, treatment, clinical trials, and healthcare services in several regions. Delays in screening and hospital visits disrupted treatment pathways for some patients. Pharmaceutical companies also faced challenges associated with clinical research and healthcare access. At the same time, the importance of maintaining cancer treatment and developing innovative therapies remained significant, supporting continued investment in oncology research.

Segmentation Analysis

By Therapy

The market is segmented into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. Targeted therapy accounted for the largest share, approximately 82% in the historical segment data, supported by broad adoption and an extensive portfolio of therapies. Important targeted treatments include trastuzumab, pertuzumab, ribociclib, palbociclib, olaparib, and other products.

Hormonal therapy includes selective estrogen receptor modulators, aromatase inhibitors, and estrogen receptor downregulators. Chemotherapy remains an important treatment option, while immunotherapy is gaining attention because of newer regulatory approvals and expanding applications.

By Cancer Type

The market is divided into hormone receptor and HER2-positive breast cancer. Hormone receptor breast cancer represented the leading cancer type segment because of its substantial patient population. The HER2-positive segment continues to develop with the introduction of additional advanced therapeutic options.

By Distribution Channel

Hospital pharmacies represent a major distribution channel because many cancer therapies require administration and monitoring in healthcare facilities. Retail pharmacies are important for oral prescription medicines, while online pharmacies are gaining attention because of convenience and expanding digital healthcare adoption.

Regional Insights

North America

North America remains the leading regional market, supported by strong pharmaceutical R&D, advanced healthcare infrastructure, clinical research activity, and adoption of innovative therapeutics. The region accounted for 47.91% of the global market in 2025.

Europe

Europe represents another significant market, supported by breast cancer incidence, established healthcare systems, cancer research programs, and increasing adoption of advanced treatment options.

Asia Pacific

Asia Pacific is expected to experience strong growth as healthcare expenditure increases, patient populations expand, awareness improves, and access to innovative therapies develops. Increasing pharmaceutical investment and clinical research are also supporting regional opportunities.

Latin America and Middle East & Africa

These emerging regions are expected to benefit from improving healthcare infrastructure, increasing healthcare expenditure, greater disease awareness, and expanding access to modern breast cancer treatments.

Competitive Landscape

The competitive landscape includes major pharmaceutical companies with extensive oncology portfolios and continuing R&D programs. Key companies include Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Eisai Co. Ltd., Kyowa Kirin, Bristol Myers Squibb, and Merck & Co., Inc. Companies are focusing on product development, clinical trials, regulatory approvals, strategic partnerships, and expansion of oncology portfolios.

Key Industry Developments

Industry developments include the launch of generic and innovative breast cancer medicines and regulatory approvals for combination therapies. Notable developments include the launch of lapatinib tablets in the U.S. following regulatory approval and the FDA approval of Phesgo, a combination of pertuzumab, trastuzumab, and hyaluronidase, for eligible patients with HER2-positive breast cancer.

Report Coverage

The report provides analysis of market size, market value, therapy segments, cancer types, distribution channels, regional developments, competitive dynamics, regulatory developments, product launches, R&D activities, and major industry trends. It also examines factors influencing the adoption of advanced breast cancer therapeutics across developed and emerging markets.

Conclusion

The global breast cancer therapeutics market is projected to expand from USD 34.59 billion in 2025 to USD 37.98 billion in 2026 and reach USD 80.23 billion by 2034, reflecting a CAGR of 9.80%. Rising breast cancer prevalence, pharmaceutical R&D, advanced targeted therapies, immunotherapy development, and increasing access to modern treatment are key factors shaping the market. North America currently represents the leading regional market, while Asia Pacific presents significant growth opportunities. Continued innovation, regulatory approvals, and development of more specialized therapies are expected to remain important contributors to the market's expansion through 2034.

Unit Value (USD billion)

Segmentation Therapy, Cancer Type, Distribution Channel, and Geography

By Therapy

• Targeted Therapy
  • Abemaciclib
  • Ado-Trastuzumab Emtansine
  • Everolimus
  • Trastuzumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib
  • Others
• Hormonal Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Estrogen Receptor Downregulators (ERDs)
• Chemotherapy
• Immunotherapy

By Cancer Type

• Hormone Receptor
• HER2+

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
  • By Country
• U.S.
• Canada
• Europe
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
  • By Country/ Sub-Region
• UK
• Germany
• France
• Italy
• Spain
• Scandinavia
• Rest of Europe
• Asia Pacific
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
  • By Country/ Sub-Region
• Japan
• China
• India
• Australia
• South East Asia
• Rest of Asia Pacific
• Latin America
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
  • By Country/ Sub-Region
• Brazil
• Mexico
• Rest of South America
• Middle East & Africa
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
  • By Country/ Sub-Region
• South Africa
• GCC Countries
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Breast Cancer, By Key Countries/Regions, 2021
• 4.2. Regulatory Scenario by Key Regions
• 4.3. Overview of Current Advances in R&D for Breast Cancer Therapeutics
• 4.4. Key Industry Developments
• 4.5. New Product Launches

5. Global Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Therapy
  • 5.2.1. Targeted Therapy
    • 5.2.1.1. Abemaciclib
    • 5.2.1.2. Ado-Trastuzumab Emtansine
    • 5.2.1.3. Everolimus
    • 5.2.1.4. Trastuzumab
    • 5.2.1.5. Ribociclib
    • 5.2.1.6. Palbociclib
    • 5.2.1.7. Pertuzumab
    • 5.2.1.8. Olaparib
    • 5.2.1.9. Others
  • 5.2.2. Hormonal Therapy
    • 5.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 5.2.2.2. Aromatase Inhibitors
    • 5.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 5.2.3. Chemotherapy
  • 5.2.4. Immunotherapy
• 5.3. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.3.1. Hormone Receptor
  • 5.3.2. HER+
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Therapy
  • 6.2.1. Targeted Therapy
    • 6.2.1.1. Abemaciclib
    • 6.2.1.2. Ado-Trastuzumab Emtansine
    • 6.2.1.3. Everolimus
    • 6.2.1.4. Trastuzumab
    • 6.2.1.5. Ribociclib
    • 6.2.1.6. Palbociclib
    • 6.2.1.7. Pertuzumab
    • 6.2.1.8. Olaparib
    • 6.2.1.9. Others
  • 6.2.2. Hormonal Therapy
    • 6.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 6.2.2.2. Aromatase Inhibitors
    • 6.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 6.2.3. Chemotherapy
  • 6.2.4. Immunotherapy
• 6.3. Market Analysis - By Cancer Type
  • 6.3.1. Hormone Receptor
  • 6.3.2. HER+
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
  • 6.4.4. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Therapy
  • 7.2.1. Targeted Therapy
    • 7.2.1.1. Abemaciclib
    • 7.2.1.2. Ado-Trastuzumab Emtansine
    • 7.2.1.3. Everolimus
    • 7.2.1.4. Trastuzumab
    • 7.2.1.5. Ribociclib
    • 7.2.1.6. Palbociclib
    • 7.2.1.7. Pertuzumab
    • 7.2.1.8. Olaparib
    • 7.2.1.9. Others
  • 7.2.2. Hormonal Therapy
    • 7.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 7.2.2.2. Aromatase Inhibitors
    • 7.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 7.2.3. Chemotherapy
  • 7.2.4. Immunotherapy
• 7.3. Market Analysis - By Cancer Type
  • 7.3.1. Hormone Receptor
  • 7.3.2. HER+
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
  • 7.4.4. Others
• 7.5. Market Analysis - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Therapy
  • 8.2.1. Targeted Therapy
    • 8.2.1.1. Abemaciclib
    • 8.2.1.2. Ado-Trastuzumab Emtansine
    • 8.2.1.3. Everolimus
    • 8.2.1.4. Trastuzumab
    • 8.2.1.5. Ribociclib
    • 8.2.1.6. Palbociclib
    • 8.2.1.7. Pertuzumab
    • 8.2.1.8. Olaparib
    • 8.2.1.9. Others
  • 8.2.2. Hormonal Therapy
    • 8.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 8.2.2.2. Aromatase Inhibitors
    • 8.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 8.2.3. Chemotherapy
  • 8.2.4. Immunotherapy
• 8.3. Market Analysis - By Cancer Type
  • 8.3.1. Hormone Receptor
  • 8.3.2. HER+
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
  • 8.4.4. Others
• 8.5. Market Analysis - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Therapy
  • 9.2.1. Targeted Therapy
    • 9.2.1.1. Abemaciclib
    • 9.2.1.2. Ado-Trastuzumab Emtansine
    • 9.2.1.3. Everolimus
    • 9.2.1.4. Trastuzumab
    • 9.2.1.5. Ribociclib
    • 9.2.1.6. Palbociclib
    • 9.2.1.7. Pertuzumab
    • 9.2.1.8. Olaparib
    • 9.2.1.9. Others
  • 9.2.2. Hormonal Therapy
    • 9.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 9.2.2.2. Aromatase Inhibitors
    • 9.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 9.2.3. Chemotherapy
  • 9.2.4. Immunotherapy
• 9.3. Market Analysis - By Cancer Type
  • 9.3.1. Hormone Receptor
  • 9.3.2. HER+
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
  • 9.4.4. Others
• 9.5. Market Analysis - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Therapy
  • 10.2.1. Targeted Therapy
    • 10.2.1.1. Abemaciclib
    • 10.2.1.2. Ado-Trastuzumab Emtansine
    • 10.2.1.3. Everolimus
    • 10.2.1.4. Trastuzumab
    • 10.2.1.5. Ribociclib
    • 10.2.1.6. Palbociclib
    • 10.2.1.7. Pertuzumab
    • 10.2.1.8. Olaparib
    • 10.2.1.9. Others
  • 10.2.2. Hormonal Therapy
    • 10.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
    • 10.2.2.2. Aromatase Inhibitors
    • 10.2.2.3. Estrogen Receptor Downregulators (ERDs)
  • 10.2.3. Chemotherapy
  • 10.2.4. Immunotherapy
• 10.3. Market Analysis - By Cancer Type
  • 10.3.1. Hormone Receptor
  • 10.3.2. HER+
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
  • 10.4.4. Others
• 10.5. Market Analysis - By Country/ Sub-Region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2021)
• 11.2. Company Profiles
  • 11.2.1. Genentech (F. Hoffmann-La Roche Ltd)
    • 11.2.1.1. Overview,
    • 11.2.1.2. Products & Services,
    • 11.2.1.3. SWOT Analysis,
    • 11.2.1.4. Recent Developments,
    • 11.2.1.5. Strategies,
    • 11.2.1.6. Financials (Based On Availability)
  • 11.2.2. Eli Lilly and Company
    • 11.2.2.1. Overview,
    • 11.2.2.2. Products & Services,
    • 11.2.2.3. SWOT Analysis,
    • 11.2.2.4. Recent Developments,
    • 11.2.2.5. Strategies,
    • 11.2.2.6. Financials (Based On Availability)
  • 11.2.3. Novartis AG
    • 11.2.3.1. Overview,
    • 11.2.3.2. Products & Services,
    • 11.2.3.3. SWOT Analysis,
    • 11.2.3.4. Recent Developments,
    • 11.2.3.5. Strategies,
    • 11.2.3.6. Financials (Based On Availability)
  • 11.2.4. AstraZeneca
    • 11.2.4.1. Overview,
    • 11.2.4.2. Products & Services,
    • 11.2.4.3. SWOT Analysis,
    • 11.2.4.4. Recent Developments,
    • 11.2.4.5. Strategies,
    • 11.2.4.6. Financials (Based On Availability)
  • 11.2.5. Pfizer Inc.
    • 11.2.5.1. Overview,
    • 11.2.5.2. Products & Services,
    • 11.2.5.3. SWOT Analysis,
    • 11.2.5.4. Recent Developments,
    • 11.2.5.5. Strategies,
    • 11.2.5.6. Financials (Based On Availability)
  • 11.2.6. Sanofi
    • 11.2.6.1. Overview,
    • 11.2.6.2. Products & Services,
    • 11.2.6.3. SWOT Analysis,
    • 11.2.6.4. Recent Developments,
    • 11.2.6.5. Strategies,
    • 11.2.6.6. Financials (Based On Availability)
  • 11.2.7. Eisai Co. Ltd.
    • 11.2.7.1. Overview,
    • 11.2.7.2. Products & Services,
    • 11.2.7.3. SWOT Analysis,
    • 11.2.7.4. Recent Developments,
    • 11.2.7.5. Strategies,
    • 11.2.7.6. Financials (Based On Availability)
  • 11.2.8. Kyowa Kirin
    • 11.2.8.1. Overview,
    • 11.2.8.2. Products & Services,
    • 11.2.8.3. SWOT Analysis,
    • 11.2.8.4. Recent Developments,
    • 11.2.8.5. Strategies,
    • 11.2.8.6. Financials (Based On Availability)
  • 11.2.9. Bristol Myers Squibb (Celgene Corporation)
    • 11.2.9.1. Overview,
    • 11.2.9.2. Products & Services,
    • 11.2.9.3. SWOT Analysis,
    • 11.2.9.4. Recent Developments,
    • 11.2.9.5. Strategies,
    • 11.2.9.6. Financials (Based On Availability)
  • 11.2.10. Merck & Co., Inc.
    • 11.2.10.1. Overview,
    • 11.2.10.2. Products & Services,
    • 11.2.10.3. SWOT Analysis,
    • 11.2.10.4. Recent Developments,
    • 11.2.10.5. Strategies,
    • 11.2.10.6. Financials (Based On Availability)